OPR - Delayed Quote • USD NVCR Jan 2026 20.000 call (NVCR260116C00020000) Follow 3.8200 0.0000 (0.00%) At close: April 15 at 12:02 PM EDT Comparisons Indicators Technicals Corporate Events Chart Types Aggregated Types Draw Table View List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Date Close Open High Low Volume O H L C Vol AAPL Loading Chart for NVCR260116C00020000 1D 5D 1M 3M 6M YTD 1Y 2Y 5Y All Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours Recent News: NVCR NovoCure (NVCR) Expected to Beat Earnings Estimates: Should You Buy? Results of Novocure’s METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024 Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024 NovoCure (NVCR) Moves to Buy: Rationale Behind the Upgrade Novocure to Report First Quarter 2024 Financial Results Why NovoCure Stock Soared 18.3% This Week Why Novocure Stock Is Jumping Today NovoCure (NVCR) Soars 12.0%: Is Further Upside Left in the Stock? Novocure Surges 12% On Brain Tumors Study; But Some Analysts Are Bearish UPDATE 1-Novocure's lung cancer therapy succeeds in late-stage trial Novocure's device shown to slow cancer progression in the brain in trial METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer
